Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies

NCT01435720 is registered in ClinicalTrials.gov with Senesco Technologies, Inc. as lead sponsor.

NCT NCT01435720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01435720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies
Lead sponsor
Senesco Technologies, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 30, 2011
Completion date
December 31, 2014
Enrollment
15 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma in relapse, mantle cell lymphoma in relapse, multiple myeloma, multiple myeloma in relapse, other b cell lymphoma in relapse, plasma cell leukemia